Overview
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Status:
Recruiting
Recruiting
Trial end date:
2025-01-01
2025-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical UniversityTreatments:
Everolimus
Lenvatinib
Trametinib
Criteria
Inclusion Criteria:- Recurrent/Refractory advanced solid tumors
- Age between 18 and 85 years
- Expected life expectancy is greater than three months
Exclusion Criteria:
- Benign tumor
- Life expectancy is less than three months
- Serious medical commodities
- others